Jordi Rodon

Summary

Publications

  1. pmc Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials
    Jordi Rodon
    Investigational Cancer Therapeutics, University of Texas M D Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:2575-88. 2008
  2. ncbi request reprint Development of PARP inhibitors in oncology
    Jordi Rodon
    UT MD Anderson Cancer Center, Investigational Cancer Therapeutics, Unit 455, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Opin Investig Drugs 18:31-43. 2009

Detail Information

Publications2

  1. pmc Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials
    Jordi Rodon
    Investigational Cancer Therapeutics, University of Texas M D Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:2575-88. 2008
    ..We also review the biomarkers explored in the first clinical trials, the strategies that have been explored thus far, and the clinical trials that are going to explore their role in cancer treatment...
  2. ncbi request reprint Development of PARP inhibitors in oncology
    Jordi Rodon
    UT MD Anderson Cancer Center, Investigational Cancer Therapeutics, Unit 455, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Opin Investig Drugs 18:31-43. 2009
    ..Concepts such as 'BRCAness', synthetic lethality, Phase 0 trials and pharmacodynamic markers will be discussed in the context of the development of PARP inhibitors...